sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Nuclear Medicine Market by Type (Diagnostic, Therapeutic), Modality (SPECT, PET, Alpha-emitters, Beta-emitters, Brachytherapy), Application (Oncology, Cardiology, Neurology, Thyroid), Procedures (Central Nervous System, Endocrine, Skeletal, Gastrointestinal, Genito-urinary, Pulmonary) and End User (Hospitals and diagnostic centers, Research institutes) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022

Nuclear Medicine Market by Type (Diagnostic, Therapeutic), Modality (SPECT, PET,...

Home / Categories / Healthcare
Nuclear Medicine Market by Type (Diagnostic, Therapeutic), Modality (SPECT, PET, Alpha-emitters, Beta-emitters, Brachytherapy), Application (Oncology, Cardiology, Neurology, Thyroid), Procedures (Central Nervous System, Endocrine, Skeletal, Gastrointestinal, Genito-urinary, Pulmonary) and End User (Hospitals and diagnostic centers, Research institutes) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022
Nuclear Medicine Market by Type...
Report Code
RO1/113/1044

Publish Date
01/Jul/2016

Pages
130
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
CHAPTER 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO perspective

CHAPTER 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Key findings

3.2.1 Top investment pockets
3.2.2 Top winning strategies

3.3 Porters five forces analysis
3.4 Clinical trials
3.5 Government regulations
3.6 Patent study
3.7 Market share analysis (2015)
3.8 Market dynamics

3.8.1 Drivers

3.8.1.1 Increase in the number of new cancer cases
3.8.1.2 Rising adoption of SPECT and PET Scans
3.8.1.3 Increase in preference for radiotaion therapy for cancer treatment
3.8.1.4 Developments in imaging technologies using radiopharmaceuticals

3.8.2 Restraints

3.8.2.1 Supply volatility, logistical challenges and stringent regulatory Policies
3.8.2.2 Competition from conventional alternative diagnostic procedures

3.8.3 Opportunities

3.8.3.1 Multilateral supply agreements between countries
3.8.3.2 Advances in neurological applications

CHAPTER 4 WORLD RADIOPHARMACEUTICALS MARKET, BY TYPE, 2014-2022

4.1 Overview

4.1.1 Market size and forecast

4.2 Diagnostics

4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast

4.3 Therapeutics

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast

4.1 Biochemistry research

4.1.1 Key market trends
4.1.2 Key growth factors and opportunities
4.1.3 Market size and forecast

CHAPTER 5 WORLD RADIOPHARMACEUTICALS MARKET, BY MODALITY, 2014-2022

5.1 Overview

5.1.1 Market size and forecast

5.2 SPECT (Single-Photon Emission Computed Tomography)

5.2.1 Market size and forecast

5.2.1.1 Iodine 123
5.2.1.2 Technetium 99m
5.2.1.3 Xenon 133
5.2.1.4 Thallium 201
5.2.1.5 Fluorine 18
5.2.1.6 Others

5.3 PET (Positron Emission Tomography)

5.3.1 Market size and forecast

5.3.1.1 Rubidium 82
5.3.1.2 Fluorine 18
5.3.1.3 Others

5.4 Beta-emitters

5.4.1 Market size and forecast

5.4.1.1 Phosphorus 32
5.4.1.2 Iodine 131
5.4.1.3 Strontium 89
5.4.1.4 Yttrium 90
5.4.1.5 Samarium 153
5.4.1.6 Rhenium 186/188
5.4.1.7 Others

5.5 Alpha-emitters

5.5.1 Market size and forecast

5.5.1.1 Radium 223
5.5.1.2 Bismuth 213
5.5.1.3 Others

5.6 Brachytherapy

5.6.1 Market size and forecast

5.6.1.1 Palladium 103
5.6.1.2 Iodine 125
5.6.1.3 Cesium 131
5.6.1.4 Others

CHAPTER 6 WORLD RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2014-2022

6.1 Overview

6.1.1 Market size and forecast

6.2 Oncology

6.2.1 Market size and forecast

6.3 Cardiology

6.3.1 Market size and forecast

6.4 Thyroid

6.4.1 Market size and forecast

6.5 Neurology

6.5.1 Market size and forecast

6.6 Others

6.6.1 Market size and forecast

CHAPTER 7 WORLD RADIOPHARMACEUTICALS MARKET, BY END-USER, 2014-2022

7.1 Overview

7.1.1 Market size and forecast

7.2 Hospitals and diagnostic centers

7.2.1 Market size and forecast

7.3 Research institutes

7.3.1 Market size and forecast

CHAPTER 8 WORLD RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2014-2022

8.1 Overview

8.1.1 Market size and forecast

8.2 North America

8.2.1 Key market trends
8.2.2 Key growth factors and opportunities
8.2.3 Market size and forecast

8.2.3.1 U.S. market size and forecast
8.2.3.2 Canada market size and forecast
8.2.3.3 Mexico market size and forecast

8.3 Europe

8.3.1 Key market trends
8.3.2 Key growth factors and opportunities
8.3.3 Market size and forecast

8.3.3.1 Belarus market size and forecast
8.3.3.2 Czech Republic market size and forecast
8.3.3.3 Greece market size and forecast
8.3.3.4 Hungary market size and forecast
8.3.3.5 Rest of Europe market size and forecast

8.4 Asia-Pacific

8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size and forecast

8.4.3.1 China market size and forecast
8.4.3.2 India market size and forecast
8.4.3.3 South Korea market size and forecast
8.4.3.4 Pakistan market size and forecast
8.4.3.5 Rest of Asia Pacific market size and forecast

8.5 LAMEA

8.5.1 Key market trends
8.5.2 Key growth factors and opportunities
8.5.3 Market size and forecast

8.5.3.1 Brazil market size and forecast
8.5.3.2 Argentina market size and forecast
8.5.3.3 South Africa market size and forecast
8.5.3.4 Rest of LAMEA market size and forecast

CHAPTER 9 COMPANY PROFILES

9.1 Mallinckrodt plc.

9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Business performance
9.1.5 Key strategies and developments
9.1.6 SWOT analysis

9.2 General Electric Co.

9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Business performance
9.2.5 Key strategies and developments
9.2.6 SWOT analysis

9.3 Medtronic, plc. (Covidien, acquired by Medtronic)

9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Business performance
9.3.5 SWOT analysis

9.4 Bayer AG

9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Business performance
9.4.5 Key strategies and developments
9.4.6 SWOT analysis

9.5 Cardinal Health, Inc.

9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Business performance
9.5.4 SWOT analysis

9.6 Lantheus Medical Imaging, Inc.

9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Business performance
9.6.4 Key strategies and developments
9.6.5 SWOT analysis

9.7 IBA Group

9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Business performance
9.7.5 Key strategies and developments
9.7.6 SWOT analysis

9.8 Bracco Imaging S.p.A

9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Business performance
9.8.5 Key strategies and developments
9.8.6 SWOT analysis

9.9 NTP Radioisotopes SOC Ltd.

9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Key strategies and developments
9.9.5 SWOT analysis

9.10 Advanced Accelerator Applications S.A.

9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Key strategies and developments
9.10.5 SWOT analysis

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com